1. Opening Hook
Christmas came early for European clients—and late for Shree Ganesh Remedies’ revenues.
Between holiday shutdowns, grumpy EU demand, and competitors slashing prices like it’s a clearance sale, Q3FY26 turned into a chemistry experiment gone slightly wrong. Management calmly calls it “temporary deferment,” while the P&L quietly screams “-22% YoY.”
But before you roll your eyes and move on, hold up. Behind the soft quarter lies a pilot plant freshly commissioned, Block 7 under construction, and a Japanese CRAMS client slowly warming up. FY26, they say, is just a consolidation year—because apparently growth is overrated right now.
Read on, because once we get past the excuses, things start getting… interesting.
2. At a Glance
- Revenue down 22% YoY – Christmas holidays did what competition couldn’t: shut factories.
- EBITDA down 32% – Operating leverage ghosted the party this quarter.
- EBITDA margin at 31.9% – Still respectable, even after a 471 bps slap.
- PAT down 43% – Profits clearly didn’t get the “long-term vision” memo.
- Finance cost up 96% YoY – Debt finally reminding everyone it exists.
3. Management’s Key Commentary
“Q3FY26 was impacted by delays in shipments due to the Christmas holiday period.”
(Santa stole 10–12% of our revenue 🎅)
“The demand environment in Europe remained challenging.”
(EU clients are window-shopping, not buying 😏)
“We saw heightened competitive intensity leading to lower realisations.”
(Everyone’s undercutting prices; nobody’s blinking)
“FY26 is a year of consolidation.”
(Please don’t
